http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김정기,홍서나,양보라,박정호,명보현,신종희,김세종,신동현 대한감염학회 2001 감염 Vol.33 No.5
Pylephlebitis is defined as an inflammation of the portal system, which is a rare but dreaded complication of intra-abdominal inflammatory processes. In the past it was observed as a sequela of neglected or complicated appendicitis. With earlier diagnosis, modern surgical technique and antibiotics, the incidence has declined even further. In addition, thrombosis in portal system (pylethrombosis) can complicate the pylephlebitis, followed by obstruction of the portal system, leading to portal hypertension in the late stage. Proper recognition of early thrombosis and an accompanying intra-abdominal inflammatory process should arouse the suspicion of septic thrombophlebitis and lead to the early institution of adequate therapy to prevent the almost universally fatal outcome. We report the case of woman who had pylephlebitis and presented with fever of unknown origin, probably associated with acute appendicitis. (Korean J Infect Dis 33:346∼349, 2001)
관상동맥 스텐트 재협착 병변의 치료에 대한약물 용출 스텐트의 임상 효과
김계훈,정명호,홍서나,윤경호,임상엽,이상현,강동구,이연상,임지현,홍영준,박형욱,김주한,김원,손일석,류제영,안영근,조정관,박종춘,강정채 대한심장학회 2005 Korean Circulation Journal Vol.35 No.6
Background and Objectives:Treating coronary in-stent restenosis (ISR) has become one of the major challengesfor the interventional cardiologist. The aim of this study was to determine the feasibility and safety of treating ISRwith drug eluting stents (DESs), and we also wanted to determine the effect of DESs on the prevention of recurrentrestenosis. Subjects and Methods:Eighty patients (age range: 60.9±6.4 year-old, males:females=63:17)with 82 ISR lesions that were treated successfully with DES (sirolimus- and paclitaxel-eluting stents) were enrolledin our study. Five patients received 2 stents for a total mean of 1.1±0.3 stents per lesion. The major adverse cardiacevents (MACEs) during hospitalization, at 30 days and at 6 months after the stenting were analyzed alongwith the coronary angiographic findings. Results:At the time of DES implantation, the mean number of ISRswas 1.4±0.9, and the patterns of ISR according to the Mehran classification were IB in 9 lesions (10.5%), IC in3 lesions (3.7%), ID in 6 lesions (7.3%), II in 19 lesions (23.2%), III in 30 lesions (36.7%), and IV in 15 lesions(18.3%). The mean stent length was 27.1±5.6 mm and the mean acute gain was 2.58±0.67 mm. No inhospitalMACE was observed. During the 30-day clinical follow-up, one patient developed acute myocardial infarctiondue to a subacute stent thrombosis. Forty two patients with 43 lesions underwent a 6-month follow-upcoronary angiogram. The mean late loss at 6 months was 0.30±0.74 mm. The binary restenosis rate was 9.3%(4/43 lesion). The restenosed lesions were treated by balloon angioplasty in three lesions and by additional DESimplantation in one lesion. Conclusion:Our results demonstrated that DES was a safe and very effective methodfor the treatment of ISR. 배경 및 목적: 스텐트 내 재협착(in-stent restenosis: ISR) 병변의 치료는 관상동맥 중재술 분야에서 주요한 문제가 되고 있다. 본 연구를 통해 ISR의 치료에 있어서 약물 용출 스텐트(drugeluting stent: DES)의 유용성과 안정성을 평가하고 반복적인 재협착 예방에 대한 DES의 효과를 알아보고자 하였다.방 법:DES를 이용하여 ISR 병변을 성공적으로 치료했던 82 병변을 갖는 80명(60.9±9.6세, 남자 63명, 여자 17명)의 환자를 대상으로 하였다. 5명의 환자는 2개(병변 당 1.1±0.3개)의 스텐트를 시술하였다. 스텐트 시술 후 병원내 임상 경과,30일째 주요 심장 사건 및 6개월째 주요 심장 사건을 분석하였다.결 과:DES 시술시 ISR의 횟수는 1.4±0.9회였고, Mehran 분류법에 따른 ISR의 형태는 IB형 9예(10.5%), IC형 3예(3.7%),ID형 6예(7.3%), Ⅱ형 19예(23.2%), Ⅲ형 30예(36.7%), Ⅳ형이 15예(18.3%)였다. 시술된 스텐트의 길이는 27.1±5.6 mm이었고, 초기 획득(acute gain)은 2.58±0.67 mm이었다.DES 시술 후 병원 내 임상 경과는 양호하였다. 30일 임상경과 관찰 동안 1예의 환자에서 아급성 스텐트 혈전증과 연관된 급성 심근경색증이 발생하였다. 6개월째 혈관의 후기손실(late loss)은 0.30±0.74 mm이었고, 43 병변 중 4 병변에서 재협착이 발생하여 재협착율은 9.3%였다. 재협착 병변 중 3 병변은 POBA로, 1 병변은 추가적인 DES 시술로 치료하였다. 결 론:ISR 병변의 치료에서 DES는 안전하고 효과적인 방법임을 알 수 있었다.